Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

Name: Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?
Start: 2022-05-24T12:00:00-04:00
End: 2022-05-24T13:00:00-04:00

Webinar May 24 12:00 pm to 1:00 pm EDT

Home
Events
Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

The dopamine hypothesis of schizophrenia has been foundational in elucidating the benefit of dopamine-blocking actions of antipsychotic medications over the past 60 years. Although blocking the D2 receptors may lead to positive symptom-alleviation in schizophrenia, doing so may come at a great cost to the overall well-being of individuals with severe mental illness. This webinar will feature two experts in the field of schizophrenia, who will speak to opportunities and challenges of currently available antipsychotics with a glimpse of the future.

Featuring

Christoph Correll, MD

Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

William Wirshing, MD

Clinical Professor of Psychiatry, Keck USC School of Medicine; and Medical Director of Exodus Recovery, Inc. in Los Angeles, CA

Dr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery, Inc in Los Angeles, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.

Laura Brennan, PhD (OPDC)

Medical Science Liaison

Speakers Christoph Correll and William Wirshing, are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Speaker Laura Brennan is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Related Events

Meet the New PsychU PTSD Section Advisor: Dr. James Murrough
April 23 12:00 pm to 1:00 pm
Using a Narrative Approach Therapy in Addressing PTSD Self-Stigma
June 4 12:00 pm to 1:00 pm

Registration

Related Resources

Digital Dialogue Series Part 4

Interview April 2, 2025

Digital Therapeutics are health software that treat or alleviate a condition by generating and delivering an intervention. This mini series aims to deepen our understanding of this innovation.
World Bipolar Day – Bipolar Together

Video March 28, 2025

Join us as both providers and patients share their thoughts and perspectives of on the significance of World Bipolar Day and the impact of living with bipolar disorder.
Understanding Caregivers’ Perspectives: Agitation in Alzheimer’s Dementia

On-Demand Webinar March 27, 2025

Join us as we explore the caregivers’ insights on the “most bothersome” symptoms and what they view as meaningful improvements or worsening in agitation.

Event Navigation

« Live Event – Proposed Role of Modulating Norepinephrine in Psychiatry Illnesses
Live Event – Importance Of Adherence To Outcomes In Schizophrenia & Bipolar Disorder »

Join today for instant access to all PsychU content, events, and more!

Membership is free!

"*" indicates required fields

Name*

First Last

Occupational Category*

Specialty*

Adult

Family Medicine

Geriatric

Internal Medicine

Long Term Care

Pediatric

Psychiatry

How did you hear about PsychU?*

Street Address*

Country*

Zip / Postal Code*

City*

State / Province / Region*

Phone Number*

State License Number

NPI Number

State License Number*

NPI Number*

NPI Exception

I certify that I am a Health Care Provider, but I do not have a NPI Number.

Choose Your Unique Login

User Name*

Your username can only contain lowercase letters (a-z) and numbers. Username cannot be the same as email address.

Email*

Enter Email Confirm Email

Password*

Your password must be at least 8 characters Hint: Must use combination of lower case letters, upper case letters, numbers and special characters like !@#$.

Enter Password Confirm Password

I AGREE TO THE FOLLOWING TERMS

I agree to the following terms:*

I certify that I am a physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and/or manager of an organization and that my primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. I understand that any services and information provided on this website are supplied as a professional courtesy and I must continue to form my own conclusions and make my own decisions. I am also aware that Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka America Pharmaceutical, Inc. and their designees (“Otsuka”) intend to regularly revise this website and reserve the right to decline membership to individuals who Otsuka determines do not meet the aforementioned certification requirements.

I agree to the following terms*

By providing your name, email address, and other information, you are giving Otsuka and companies working with Otsuka permission to send you information from PsychU. Otsuka will not sell or transfer your personal information to any unaffiliated third party, without your prior written consent. Otsuka may monitor your use of the PsychU website to provide you with complimentary information about relevant educational programs based on your use the PsychU website. You agree that, should you use any material provided through PsychU you will attribute the source of that information to “PsychU sponsored by Otsuka Pharmaceutical Development & commercialization, Inc.” For additional information about how Otsuka uses your personal information, how to amend or delete your information, and how to opt out of future communications, please read Otsuka’s Privacy policy, which can be found here. By clicking “Join” and submitting your information, you agree to the terms provided above, and the terms provided in Otsuka’s Terms of Use and Privacy Policy.

Hidden

Direct Care Provider

Direct Care Provider Newsletter

False

Hidden

Clinician Newsletter

False

Hidden

Management Newsletter

False

Hidden

user_preferences_account_notifications

False

Hidden

user_preferences_webinar_emails

False

Event Registration

Submit any questions you may have regarding the topic of this Event and we will try to answer them during the live presentation:

How Did You Hear About This Event*

Date*

MM slash DD slash YYYY

Hidden

otsuka attendence page Event ID

Hidden

Event Page Registration Event ID

Meal Opt Out

Attested*

Attested

(Required)

Signature*

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS

PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.

PSYCHU MEMBERSHIP ELIGIBILITY

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.

MEMBERSHIP & REGISTRATION

Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.

ATTENDANCE LIMITATIONS

PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.

MEAL REPORTING

The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Hidden

utm_source

Hidden

initial_source

CAPTCHA

Join PsychU Today to receive a wide array of tools and benefits

Join our multidisciplinary community that is improving mental health care… together
Quickly learn more about the topics you're interested in
Access an award-winning library of on-demand mental health resources
Gain key insights from industry expert & thought leaders

Now Leaving PsychU

This link will take you outside of the PsychU community website

PsychU

Sorry, this content is no longer available.

Thank You For Attending Today’s Webinar

About This Event

Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

Featuring

Christoph Correll, MD

William Wirshing, MD

Laura Brennan, PhD (OPDC)

Related Events

Meet the New PsychU PTSD Section Advisor: Dr. James Murrough

Using a Narrative Approach Therapy in Addressing PTSD Self-Stigma

Registration

Related Resources

Digital Dialogue Series Part 4

World Bipolar Day – Bipolar Together

Understanding Caregivers’ Perspectives: Agitation in Alzheimer’s Dementia

Event Navigation

Join today for instant access to all PsychU content, events, and more!

Membership is free!

Choose Your Unique Login

I AGREE TO THE FOLLOWING TERMS

Event Registration

Join PsychU Today to receive a wide array of tools and benefits

Stay Connected: